Translate Bio to Present at the Bank of America Securities Virtual 2020 Healthcare Conference

Rhea-AI Summary

Translate Bio (Nasdaq: TBIO), a clinical-stage mRNA therapeutics company, has announced that CEO Ronald Renaud will participate in a fireside chat at the Bank of America Securities Virtual 2020 Health Care Conference on May 14, 2020, at 9:00 a.m. ET. This session will be available via live webcast on the Company's website, with a replay accessible for 30 days after the event.

Translate Bio is notably focused on developing transformative medicines for diseases linked to protein dysfunction, including a lead program targeting cystic fibrosis currently in a Phase 1/2 clinical trial.

LEXINGTON, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that Ronald Renaud, chief executive officer, will participate in a fireside chat at the Bank of America Securities Virtual 2020 Health Care Conference on Thursday, May 14, 2020, at 9:00 a.m. ET.

A live webcast of the session will be accessible through the “Events and Presentations” page of the Company's website at investors.translate.bio. A replay of the webcast will be archived on the Translate Bio’s website for 30 days following the presentation.

About Translate Bio
Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.  Translate Bio is primarily focused on applying its technology to treat pulmonary diseases caused by insufficient protein production or where the reduction of proteins can modify disease.  Translate Bio’s lead program is being developed as a treatment for cystic fibrosis (CF) and is in a Phase 1/2 clinical trial. The Company also believes its technology is applicable to a broad range of diseases, including diseases that affect the liver. Additionally, the platform may be applied to various classes of treatments, such as therapeutic antibodies or vaccines in areas such as infectious disease and oncology. For more information about the Company, please visit www.translate.bio or on Twitter at @TranslateBio.

Contacts for Translate Bio

Investors		Media
Teri Dahlman		Maura Gavaghan
tdahlman@translate.bio		mgavaghan@translate.bio
857-242-7792		857-242-7789

FAQ

When will Translate Bio CEO Ronald Renaud speak at the Bank of America Securities Virtual 2020 Health Care Conference?

Ronald Renaud will participate in the conference on May 14, 2020, at 9:00 a.m. ET.

How can I watch the Translate Bio fireside chat featuring Ronald Renaud?

The fireside chat will be webcast live on Translate Bio's 'Events and Presentations' page on their website.

What is the focus of Translate Bio's clinical-stage mRNA therapeutics?

Translate Bio focuses on developing medicines for diseases caused by protein or gene dysfunction, with an emphasis on pulmonary diseases.

What is the current status of Translate Bio's lead program?

Translate Bio's lead program, targeting cystic fibrosis, is currently in a Phase 1/2 clinical trial.

How long will the recording of the Translate Bio presentation be available?

A replay of the webcast will be archived on Translate Bio's website for 30 days following the presentation.